Journal Mobile Options
Table of Contents
Vol. 22, No. 1, 2006
Issue release date: June 2006
Section title: Original Research Article
Dement Geriatr Cogn Disord 2006;22:73–82

Apolipoprotein E ε4 Allele Is Unrelated to Cognitive or Functional Decline in Alzheimer’s Disease: Retrospective and Prospective Analysis

Kleiman T.a · Zdanys K.a · Black B.a · Rightmer T.a · Grey M.a · Garman K.a · MacAvoy M.a · Gelernter J.b · van Dyck C.a, c
aAlzheimer’s Disease Research Unit; bDivision of Molecular Psychiatry, Department of Psychiatry, and cDepartment of Neurobiology, Yale University School of Medicine, New Haven, Conn., USA
email Corresponding Author

Christopher H. van Dyck, MD Alzheimer’s Disease Research Unit Department of Psychiatry, Yale University School of Medicine One Church Street, Suite 600, New Haven, CT 06510 (USA) Tel. +1 203 764 8100, Fax +1 203 764 8111, E-Mail

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.


Objective: The apolipoprotein E (ApoE) ε4 allele is a well-documented genetic risk factor for Alzheimer’s disease (AD). Its role, if any, in the progression of cognitive and functional impairment in AD has been the subject of discrepant reports in the literature. This study aimed to determine whether ApoE ε4 dose is related to the progression of cognitive and functional decline in AD patients by combined retrospective and prospective analyses. Methods: A sample of 366 AD patients was genotyped for ApoE. Subjects received tests of cognition (Mini-Mental State Examination, MMSE; Alzheimer’s Disease Assessment Scale-Cognitive subscale, ADAS-Cog) and daily function (Instrumental Activities of Daily Living, IADL; Alzheimer’s Disease Cooperative Study-Activities of Daily Living, ADCS-ADL) at baseline and at multiple subsequent time points during their participation in a variety of research protocols. In retrospective analyses, scores on baseline cognitive and functional measures were compared cross-sectionally among genotype groups, controlling for duration of symptoms. In prospective analyses, longitudinal rates of change for each measure were computed by linear regression and compared across genotype groups. Results: No association was observed between ApoE ε4 dose and any of the retrospective or prospective measures of cognitive or functional decline in this AD patient sample. Conclusions: Although ApoE ε4 increases the risk for AD and decreases the age of disease onset in population studies, it did not significantly influence the rate of disease progression in cognitive or functional domains in our sample.

© 2006 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Received: 12/20/2005
Published online: 6/19/2006

Number of Print Pages: 10
Number of Figures: 0
Number of Tables: 4

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information:

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.